Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of the latest advances in targeted therapies for biliary tract cancer. Findings from the Phase II IMbrave 151 trial (NCT04677504), which assessed atezolizumab with gemcitabine, cisplatin, and bevacizumab in patients with biliary tract cancer, determined the investigational regimen to not significantly improve outcomes. Current targeted therapies include the FGFR2 inhibitors pemigatinib and futibatinib, as well as ivosidenib, an IDH1 inhibitor. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.